In this study, no significant changes in CREB or ERK phosphorylation were observed with lower (5 μM) concentrations of MSG-606, and a significant decrease in p65 NFκB phosphorylation was only observed with 10 μM MSG-606 (Fig. 6b, Supplementary Fig. 5b), suggesting that MSG-606 might have lower efficacy in breast cancer cells. The gene discussed is CREB1; the disease is breast carcinoma.